title: [A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma].
abstract: A 71-year-old man presented with chief complains of hoarseness and dysphagia. He was diagnosed to have an advanced esophageal adenocarcinoma in the middle thoracic esophagus for which chemoradiation therapy was started. Partial response was observed and he was referred to our hospital thereafter. After detailed examination, he underwent a subtotal esophagectomy followed by two-field lymphadenectomy in May 2001. Histopathological examination revealed a complete response. Ten months later, hematological examination showed a high serum CEA level and CT scan disclosed mediastinal lymph node recurrences. He received a course of systemic chemotherapy so called FP therapy and five months later, a course of combination chemotherapy with 700 mg/m2 5-FU on days 1-5 and 70 mg/m2 nedaplatin on day 1 was administered. Because the high serum CEA level sustained afterward, FDG-PET was undertaken in March 2003. The right adrenal gland showed an intense abnormal FDG uptake and CT scan detected a low density mass in the area. Since no metastases could be identified in other sites, right adrenalectomy was performed. Pathological finding was poorly-differentiated tubular adenocarcinoma. Five years and eleven months after adrenalectomy, he died of pneumonia with no signs of recurrence. Surgical resection may contribute to improving the prognosis of solitary adrenal metastasis of esophageal cancer without the other noncurative factors.
authors.affiliation: Dept. of Frontier Surgery, Chiba University Graduate School of Medicine.
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Saito
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Shuto
authors.forename: Takumi
authors.initials: T
authors.lastname: Ota
authors.forename: Takayuki
authors.initials: T
authors.lastname: Toma
authors.forename: Gaku
authors.initials: G
authors.lastname: Ohira
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Natsume
authors.forename: Masaya
authors.initials: M
authors.lastname: Uesato
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Akutsu
authors.forename: Tsuguaki
authors.initials: T
authors.lastname: Kono
authors.forename: Hisahiro
authors.initials: H
authors.lastname: Matsubara
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery; D000310:Adrenal Gland Neoplasms / Q000556:secondary* / Q000601:surgery*; D000315:Adrenalectomy; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000097:blood; D004938:Esophageal Neoplasms / Q000473:pathology* / Q000601:surgery*; D016629:Esophagectomy; D019788:Fluorodeoxyglucose F18; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D049268:Positron-Emission Tomography
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D009944:Organoplatinum Compounds; D019788:Fluorodeoxyglucose F18; C053989:nedaplatin; D005472:Fluorouracil